T. Rowe Price Investment Management
MDGL icon

T. Rowe Price Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

T. Rowe Price Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,644
Closed -$7.18M – 644
2024
Q2 		$7.18M Sell
25,644
-17,342
-40% -$4.13M ﹤0.01% 557
2024
Q1 		$11.5M Buy
+42,986
New +$10.1M 0.01% 533

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management's MDGL Position: Q3 2024 in Review

T. Rowe Price Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 25,644 shares — an estimated $7.18M sold.

T. Rowe Price Investment Management first reported a position in MDGL in Q1 2024 and held it in 2 quarters. The position peaked at $11.5M in Q1 2024. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • T. Rowe Price Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 25,644 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $7.18M.
  • T. Rowe Price Investment Management first reported a position in Madrigal Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Madrigal Pharmaceuticals position peaked at $11.5M in Q1 2024.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.